---
title: "ramucirumab"
slug: "ramucirumab"
date: "2023-09-21"
enableToc: false
tags:
  - building
---

> [!info]
>
> 🌱 來自: [[Metastatic Colon Cancer]]

# ramucirumab

- Mechanism: Binds to VEGFR2
- Dosing: Dosing dependent on dz; colorectal/gastric: 8 mg/kg IV every 2 wks as part of combination therapy; NSCLC 10 mg/kg every 21 d w/ docetaxel
  - mCRC: 8 mg/kg every 2 weeks in combination with fluorouracil, leucovorin (folinic acid), and irinotecan (FOLFIRI)
- PK/PD: T1/2 ∼14 d
- AEs:
  - HTN,
  - anemia,
  - diarrhea,
  - proteinuria,
  - neutropenia,
  - infusion-related rxns
  - [[reversible posterior leukoencephalopathy syndrome]] (RPLS) occurs
- DDI: No known pathways of metabolism
- Clinical pearls: Premedications required; pts w/ HTN should be controlled prior to administration & BPs monitored closely

$ 11,531 (100 mg), 48,038 (500 mg)

大腸直腸癌: Ramucirumab 併用FOLFIRI (irinotecan、葉酸及5-fluorouracil) 適用於治療正接受或接受過 bevacizumab、oxaliplatin 及 fluoropyrimidine 治療仍疾病惡化之轉移性大腸直腸癌 (mCRC)。
